

Scientific Programme

Wednesday June 30, 2010

Target Selection: Hit to Lead: Identification, development

08:00 Registration

09:30 Opening

Session Chair

Prof. André TARTAR
(UNIVERSITY LILLE 2, Lille, France)

10:00 Vascular Tumor Targeting

Prof. Dario NERI
(ETH ZÜRICH, Zürich, Switzerland)

10:45 Coffee Break

Session Chair

Dr Marcel HIBERT
(FACULTE DE PHARMACIE, Illkirch, France)

11:15 Novel Antagonists of Protease Activated Receptors 1: Unusual GPCRs Implicated in Cardiovascular Diseases

Dr Michel PEREZ
(PIERRE FABRE, Toulouse, France)

12:00 Identification of Functionally Selective Alpha2C-AR Agonists as Potential New Drugs for Treatment of Pain

Dr Eric JNOFF
(UCB PHARMA SA, Braine-l'Alleud, Belgium)

12:45 Lunch and Poster Session

Session Chair

Dr. Robert H. DODD
(ICSN CNRS, Gif-Sur-Yvette, France)

14:15 Pyrrolopyrimidine-Based P2X3 Antagonists for the Treatment of Pain

Dr Louis-David CANTIN
(ASTRAZENECA R&D, Montréal, Canada)

15:00 Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target

Dr Maxwell CUMMINGS
(TIBOTEC, Mechelen, Belgium)

15:45 Coffee Break and Poster Session

Session Chair

Dr Luc VAN HIJFTE
(JANSSEN RESEARCH & DEVELOPMENT, Nijmegen, The Netherlands)

Scientific Programme

- 16:30** **Indole-carboxylic Acid Amides as Novel CETP Inhibitors: From Hit to Clinical Candidate and Beyond**
Dr Philippe PFLIEGER
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
- 17:15** **Inhibitors of PKC-beta and GSK-3beta: A Tale of Two Kinases**
Dr Bruce MARYANOFF
(SCRIPPS, San Diego, United States)
- 18:30** **Cocktail and Poster Session (Faculty of Pharmacy)**

Scientific Programme

Thursday July 1, 2010

Session Section A

Synthetic Chemistry: new frontiers impacting drug discovery

Session Chair

Dr Maurice MEDEBIELLE
(UNIVERSITÉ CLAUDE BERNARD LYON 1, Villeurbanne, France)

09:00 Hybrids Natural Products with Neurotrophin Activity

Dr Bruno FIGADERE
(UNIVERSITÉ PARIS-SUD, Chatenay-Malabry, France)

09:45 Two Stimulating Concepts in Natural Substances Synthesis: the NEO Cascade and the CIM Strategy

Prof. Arnaud HAUDRECHY
(UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE, Reims, France)

10:30 Coffee Break

Session Chair

Dr Pascal GEORGE
(SANOFI-AVENTIS R&D, Longvilliers, France)

11:00 New Methods for Peptide Synthesis

Prof. David CRICH
(ICSN, Gif-sur-Yvette, France)

11:45 Peptidomimetic Foldamers: Connecting Structure to Function

Dr Gilles GUICHARD
(UNIVERSITY OF BORDEAUX, CBMN, Bordeaux, France)

12:30 Lunch and Poster Session

Session Chair

Dr Bruno FIGADERE
(UNIVERSITÉ PARIS-SUD, Chatenay-Malabry, France)

14:00 Active Pharmaceutical Ingredients in Convergent Technologies: How Are They Chosen

Dr Cynthia MARYANOFF
(CORDIS, A JOHNSON AND JOHNSON COMPANY, Spring House, United States)

14:45 Fragment-based Design of Small RNA Binders

Dr Laurent MICOUIN
(UNIVERSITÉ PARIS DESCARTES, Paris, France)

Session Section B

Screening, managing structure-properties relationship

Session Chair

Prof. Hervé GALONS
(SCT & PARIS DESCARTES UNIVERSITY, Paris, France)

09:00 Carbonic Anhydrases: Novel Therapeutic Applications for Inhibitors and Activators

Prof. Claudiu SUPURAN
(UNIVERSITY OF FIRENZE, Sesto Fiorentino, Italy)

09:45 Prodrug Approaches for Enhancing the Bioavailability of Drugs

Prof. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany)

10:30 Coffee Break

Session Chair

Dr Philippe PITCHEN
(FOREST RESEARCH INSTITUTE, Hauppauge, United States)

11:00 Functional Assays as Multifaceted Tools for HTS

Dr Olivier NOSJEAN
(SERVIER RESEARCH INSTITUTE, Croissy-sur-Seine, France)

RICT 2010 - Interfacing Chemical Biology and Drug Discovery

Scientific Programme

11:45 Virtual Screening in Drug Discovery: Overview and Applications

Dr Romano KROEMER
(SANOFI AVENTIS, Vitry sur Seine, France)

12:30 Lunch and Poster Session

Session Chair

Prof. Olivier DUVAL
(, Angers, France)

14:00 Topically Bioavailable and Systemically Safe PPAR α Agonists as Sebum Modulators

Dr Jean-Guy BOITEAU
(GALDERMA R&D, Sophia-Antipolis, France)

14:45 Novel Compound Classes as Calcilytics for the Treatment of Osteoporosis

Dr Leo WIDLER
(NOVARTIS, Basel, Switzerland)

Session Chair

Prof. Dario NERI
(ETH ZÜRICH, Zürich, Switzerland)

16:00 Sugars and Proteins

Prof. Benjamin DAVIS
(OXFORD UNIVERSITY, Oxford, United Kingdom)

16:45 End of Conference

17:15 Departure by bus to visit the "Taittinger wine cellars" (for pre-registered participants)

17:30 Visit of "Caves Taittinger"

20:00 Banquet

20:00 Banquet in the "Demeure des Comtes de Champagne" (18-22 rue de Tambour, 511100 Reims, near the City Hall)

In parallel:

14:00-15:30 - JOB Forum

Dr Patrick PLE (ASTRA ZENECA, Reims, France)
Dr Laurent JEANNIN (SOLVAY, Belgium)
Mr T  rence BEGHYN (UNIVERSITY LILLE 2, Lille, France)

Scientific Programme

Friday July 2, 2010

Case-Studies from Bench to Bedside

Session Chair

Dr Edmond DIFFERDING
(FORMELY WITH UCB, Louvain-la-Neuve, Belgium)

09:00 The First NO- and Heam-independent Activator of Soluble Guanylate Cyclase for the IV Treatment of Acute Heart Failure

Dr Michael G. HAHN
(BAYER HEALTHCARE, Wuppertal, Germany)

09:45 A Single Synthetic Peptide for Immunomodulating Lupus, a Complex Autoimmune Disease

Dr Sylviane MULLER
(IBMC-CNRS, Strasbourg, France)

10:30 Coffee Break

Session Chair

Dr Dominique LESUISSE
(SANOFI AVENTIS, Chilly-Mazarin, France)

11:00 The Identification of Selective p38 MAPK Inhibitors with High Blood Potency Suitable for Clinical Development: The Discovery of Losmapimod

Dr Vipul K. PATEL
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

11:45 Telbivudine, a Potent and Specific Anti-HBV Nucleoside Analogue: From the Bench to its Marketing Approvals (Tyzeka®, Sebivo®)

Dr Gilles GOSSELIN
(IDENIX SARL, Montpellier, France)

12:30 Discovery of Inhibitors of MAPKAPK5, a Novel Target for Rheumatoid Arthritis

Dr Martin ANDREWS
(GALAPAGOS NV, Mechelen, Belgium)

**13:15 Conclusions
End of the Symposium**